This 2023 randomized controlled trial investigated the impact of sleep duration and quality on weight loss maintenance in adults with obesity. After an initial 8-week low-calorie diet resulting in an average weight loss of 13.1 kg, participants were monitored over a 1-year maintenance phase. Those with short sleep duration (5)
This 2024 secondary analysis of a randomized clinical trial examined the effects of exercise, GLP-1 receptor agonist (liraglutide) treatment, and their combination on bone health in adults with obesity. After an initial 8-week low-calorie diet, 195 participants were randomized into four groups: exercise alone, liraglutide alone, combination of both, or
This 2022 pharmacovigilance study analyzed FDA Adverse Event Reporting System (FAERS) data to assess the association between GLP-1 receptor agonists (GLP-1 RAs) and acute cholecystitis. The analysis revealed a notable number of reports linking GLP-1 RAs, such as liraglutide and semaglutide, to cases of acute cholecystitis. The proposed mechanism involves
This 2018 systematic review and network meta-analysis evaluated the impact of FDA-approved weight-loss medications—phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat—on cardiometabolic risk factors in obese adults. Analyzing 28 randomized controlled trials encompassing 29,018 participants, the study found that these medications led to modest reductions in fasting blood glucose (mean decrease of
This 2013 review discusses the role of incretin hormones, particularly glucagon-like peptide-1 (GLP-1), in regulating appetite and inducing satiation. GLP-1 is secreted by intestinal L-cells in response to nutrient intake and acts through both peripheral and central pathways to promote feelings of fullness. It slows gastric emptying, enhances insulin secretion,
The STEP 8 trial was a 68-week, randomized, double-blind, double-dummy, phase 3 clinical study comparing once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. Participants received lifestyle interventions alongside medication. Semaglutide led to a greater mean weight loss (−15.8%)
This 2019 randomized controlled trial evaluated the efficacy of combining intensive behavioral therapy (IBT) with liraglutide 3.0 mg, with or without a 12-week meal replacement diet, in 150 adults with obesity over 52 weeks. Participants were assigned to one of three groups: IBT alone, IBT plus liraglutide, or IBT plus
This 56-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of 3.0 mg liraglutide in 3,731 overweight or obese adults without type 2 diabetes. Participants received daily subcutaneous injections of liraglutide or placebo, alongside lifestyle counseling. At week 56, the liraglutide group achieved a mean weight loss of 8.4
This 2015 randomized controlled trial investigated the effects of liraglutide, a GLP-1 receptor agonist, on leptin dynamics during weight loss maintenance in 52 healthy obese individuals. After achieving a 12% weight loss through a low-calorie diet, participants were randomized to receive liraglutide (1.2 mg/day) or no additional treatment for 52
This 12-week open-label, prospective study evaluated the efficacy of combining liraglutide (1.2 mg/day subcutaneously) with metformin (1000 mg twice daily) in 40 obese, non-diabetic women with PCOS who had previously lost less than 5% body weight on metformin monotherapy. Participants were randomized into three groups: metformin alone (MET), liraglutide alone
